Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
rimegepant
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
N02CD07
|
| gptkbp:form |
orodispersible tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vydura (EU)
|
| gptkbp:indication |
migraine
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
CGRP receptor antagonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
acute treatment of migraine
preventive treatment of episodic migraine in adults |
| gptkbp:bfsParent |
gptkb:Nurtec_ODT
|
| gptkbp:bfsLayer |
8
|